Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002871 (anemia)
 52,094 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Globin synthesis was measured by incubating washed packed red cells with a balanced amino acid mixture and 14C-Histidine. After globin had been isolated from the haemolysate the 14C-incorporation rate per 10 mg globin per min was estimated. With regard to globin synthesis no differences existed between patients on chronic intermittent haemodialysis therapy (n equals 41), patitents suffering from secondary anaemia due to chronic infection, rheumatism or malignant diseases (n equals 21) and healthy subjects (n equals 37). Patients with acute bleeding on the other hand, had significant higher 14C-incorporation rates caused by an increase of the reticulocyte count mu1 blood (n equals 13). When substances retained in renal failure were added to the incubation mixture a marked inhibition took place with guanidinosuccinic acid, methylguanidine and fraction containing peptides with a molecular weight between 1200-1400 present in uraemic serum and normal urine, but not in serum from patients without renal failure.
Proc Eur Dial Transplant Assoc 1976
PMID:Globin synthesis in uraemia. 93 26

1. The present studies have demonstrated that the titers of erythropoietin may be elevated to varying degrees in patients with anemia associated with end-stage renal disease. However, the increase in erythropoietin titers was apparently not sufficient to meet the increase in demand for new red blood cells created by their shortened life span and the inhibitors of heme synthesis and/or erythroid colony forming cells (CFU-E). 2. Inhibitors of heme synthesis were demonstrated in the plasma of some but not all patients with anemia associated with renal disease and in rabbits 72 hrs following bilateral nephrectomy. 3. CFU-E were both increased and decreased in the bone marrows of the chronic anemic uremic rabbits, when compared with that of sham operated controls, 14 and 21 days after 5/6th nephrectomy and depended on the rate of regeneration of the renal erythropoietic and excretory functions. CFU-E in marrows of 5/6th nephrectomy rabbits were decreased after 35 days. 4. An inhibitor of CFU-E was increased in the sera from chronic anemic uremic rabbits, when compared with that of the sham-operated controls, 35 days after 5/6th nephrectomy. 5. It is possible that in the anemia of uremia in addition to inadequate production of erythropoietin there is a defect in the differentiation of the CFU-E into the heme synthesizing erythroid series due to the presence of a specific inhibitor of CFU-E and/or heme synthesis.
Proc Clin Dial Transplant Forum
PMID:Studies on the mechanism of the anemia of renal insufficiency. 102 87

To reduce the hours and cost of each dialysis and/or to increase adequacy of haemodialysis treatment 14 chronic dialysis patients were dialysed with two Gambro dialysers, 4 hr for 3 days per week. General well-being, anaemia, and nerve conduction velocity improved in some patients during the study period. Increasing dialysis surface area by using two Gambro dialysers enabled reduction of hours of dialysis, which was favourably accepted by all patients and decreased cost of dialysis, mainly by increasing the capacity of a unit to dialyse more patients with the same personnel and equipment.
Proc Eur Dial Transplant Assoc 1975
PMID:Clinical evaluation of patients dialysed with double Gambro 4 hours, three times per week. 119 44

Since no information exists concerning porphyrin metabolism in uraemic patients we have measured the activities of delta-aminolaevulinic acid dehydrase (D-ALA-D) and porphobilinogen desaminase (PBG-D) in reticulocytes from uraemic patients, anaemic patients without uraemia and in healthy subjects. Despite a severe anaemia uraemic patients had the same amount of reticulocytes/mul blood. In uraemic patients D-ALA-D activity was reduced to about 20% compared to healthy subjects, PBG-D in uraemia was decreased to about 70%. It is concluded that porphyrin metabolism is altered in uraemic patients.
Proc Eur Dial Transplant Assoc 1975
PMID:Porphobilinogen and porphyrin synthesis in reticulocytes from uraemic patients. 119 62

Chronic renal failure (CRF) patients treated with histidine alone did not show any effect with respect to anaemia or protein metabolism, despite a rise in serum histidine levels. Beneficial effect of iron with regards to anaemia and protein metabolism was seen in CRF patients treated with iron alone or in combination with histidine. Patients with combination therapy showed accelerated improvement of anaemia in comparison with patients treated with iron alone. In RDT patients, who underwent basic treatment with parenteral iron, histidine failed to show any effect with regards to anaemia, despite significantly lowered serum histidine levels. But under histidine treatment a significant rise of transferrin levels occurred in RDT patients, so that histidine must be considered as a limiting factor in protein metabolism in these cases. Histidine requirements of RDT patients are more than 1-2 g/day, and are higher than the requirements of patients conservatively treated.
Proc Eur Dial Transplant Assoc 1975
PMID:Histidine and iron supplementation in dialysis and pre-dialysis patients. 119 63

A new technique for recording and analysing continuous measurements of oxygen saturation (SpO2) by pulse oximeter during haemodialysis was used to compare changes in SpO2 in eight patients during two 4 h periods of dialysis using a cuprophane membrane, once using an acetate dialysate, and once using bicarbonate. The computer-derived patterns of SpO2 show whether hypoxaemia was caused mainly by extrapulmonary abnormalities (ventilatory control) or intrapulmonary abnormalities (V/Q distribution). The patterns of oxygen saturation were analysed for (i) stability, (ii) the lower median 20th centile of SpO2, and (iii) time below a SpO2 of 90%. Not all patients had reduced oxygenation during acetate dialysis. Three of eight patients had a stable pattern with acetate dialysis and six of eight were stable with bicarbonate. Five of eight patients had a lower SpO2 with acetate but one patient had a lower SpO2 with bicarbonate. Four patients had prolonged, clinically significant periods of oxygen desaturation with SpO2 less than 90%; two of these had particularly prolonged periods during acetate (62 min and 12 min), but one patient showed a longer period during bicarbonate than acetate dialysis (7 min). In two patients the SpO2 declined to less than 84%. The patterns of SpO2 suggested that the decrease in oxygen saturation was due more to extrapulmonary abnormalities causing an instability in ventilatory control rather than to venous admixture. It is recommended that pulse oximetry is used to identify patients at risk of hypoxaemia, to monitor these patients during haemodialysis, and to administer oxygen to those whose SpO2 falls below 90%, particularly if they have anaemia or cardiovascular disease.
Nephrol Dial Transplant 1992
PMID:Continuous measurements of oxygen saturation during haemodialysis. 131 68

Homeostasis of essential amino acids and their transamination derivatives (ketoacids) is disturbed in haemodialysis (HD) patients. In long-term HD patients a hypercatabolic state is often paired with severe anaemia. To understand metabolic regulation mechanisms we measured with an improved fluorescence-HPLC method plasma concentrations of valine (Val), isoleucine (Ile), and leucine (Leu) and their corresponding ketoacids ketoisovaleric acid (KIV), ketomethylvaleric acid (KMV), and ketoisocaproic acid (KIC). The values of 18 modestly anaemic HD patients (group A: Hb greater than 11 g/dl) and of 16 severely anaemic HD patients (group B: Hb less than 8 g/dl) were compared with 19 healthy control persons (100%; significance of patient values vs controls P less than 0.05) and with each other (significantly different at P less than 0.05). Both branched chain amino acids and ketoacids are diminished in HD patients. This disturbance of protein metabolism is intensified with severe anaemia. The decrease of transamination products KIV and KMV parallels that of their corresponding Val and Ile, whereas KIC is reduced out of proportion to Leu. Leu has anabolic function and KIC antiproteolytic effects. Decreased Leu and KIC indicate catabolism. Reduced transamination of Leu and KIC suggests an endogenous protective mechanism against catabolism independent of anaemia. These differences should be considered with supplementation therapy of branched-chain compounds in HD patients.
Nephrol Dial Transplant 1992
PMID:Essential branched-chain amino acids and alpha-ketoanalogues in haemodialysis patients. 131 69

Although erythropoietin (Epo) is known to correct anaemia in dialysis and pre-dialysis patients, there is limited experience with its use in immunosuppressed patients suffering from chronic renal graft dysfunction. We report the results of a pilot study of Epo in seven patients with failing grafts and normocytic normochromic anaemia attributable to renal failure. All entering patients had controlled blood pressure and serum ferritin greater than 100 micrograms/l. Three patients were taking triple immunotherapy (prednisone/azathioprine/cyclosporin), two patients prednisone/azathioprine, and two patients CsA monotherapy. Study duration mean was 15 +/- 2 (SEM) weeks, and Epo was started at 4000 units subcutaneously (s.c.) once weekly, adjusted to achieve a target haemoglobin (Hb) of 100 g/l. Mean Hb at initiation was 68 +/- 5 g/l and significantly increased to 96 +/- 6 at end of follow-up, P less than 10(-4). All patients responded. Maintenance Epo dosage was 120 +/- 32 U/kg bodyweight/week, roughly 4000 units/week. There was no significant change in serum creatinine: pre-study 392 +/- 45 mumol/l; post-study 430 +/- 62 mumol/l. There were no complications but blood pressure did rise significantly: pre- 124 +/- 11/74 +/- 4 mmHg to post- 142 +/- 10/86 +/- 3, P less than 0.05 for systolic and diastolic. Low-dose s.c. Epo effectively corrects anaemia in graft failure despite azathioprine and/or CsA therapy, without obvious acceleration of graft failure.(ABSTRACT TRUNCATED AT 250 WORDS)
Nephrol Dial Transplant 1992
PMID:Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure. 131 75

Psychometric performance was studied on two occasions in 18 chronic haemodialysis patients. Nine patients treated with rHuEpo performed a battery of psychometric tests before treatment, haemoglobin [mean (SD)] 5.8 (0.6) g/dl and after partial correction of anaemia, haemoglobin 9.3 (1.28) g/dl. The same battery of psychometric tests was administered on two occasions to nine patients (haemoglobin 7.3 (1.2) g/dl) matched with the treatment group for age, educational status and social class, who did not receive rHuEpo. In the rHuEpo-treated group, IQ, measured by the Wechsler Adult Intelligence Scale-Revised, improved by a mean of 8.7 points (P less than 0.01), while in the control group an improvement by a mean of 2.5 points was not significant. Comparison between the groups of the change in IQ score was significant (P = 0.04). There was no change in the mean scores obtained in either group for the other psychometric tests administered including the Paced Auditory Serial Addition Test, Rey auditory verbal learning, and Borkowski verbal fluency test. These results indicate that anaemia makes a reversible contribution to uraemic cognitive dysfunction.
Nephrol Dial Transplant 1992
PMID:Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients. 131 97

Anaemia is a feature almost invariably complicating chronic renal failure. Its pathophysiology is multifactorial but the most important cause is erythropoietin (Epo) deficiency. However, either no relation or even a weakly positive relation generally exists between serum immunoreactive (i) Epo and haematocrit values in uraemic anaemia, whereas in anaemias of non-renal origin the correlation is most often strongly negative. Recent evidence indicates that growth hormone also stimulates erythropoiesis. Moreover, late erythroid progenitor cells (CFU-E) require insulin and/or insulin-like growth factor I (IGF-I) for development in vitro. IGF-I has been shown to have a synergistic action with Epo. We have measured serum iEpo and IGF-I levels in 17 haemodialysis patients with severe hyperparathyroidism (mean +/- SEM serum iPTH, 988 +/- 88 pg/ml). Mean age and duration of dialysis treatment were 46.1 +/- 3.4 and 8.8 +/- 1.0 years respectively. Mean haematocrit and haemoglobin values wer 28.1 +/- 1.7% and 9.39 +/- 0.54 g/dl respectively. Mean serum iEpo and IGF-I levels were 20.3 +/- 4.7 mU/ml and 320 +/- 20 ng/ml respectively (normal values for serum iEpo and IGF-I, 17.9 +/- 6 mU/ml and 91 +/- 23 ng/ml respectively). We found that serum IGF-I concentrations were well correlated with haematocrit values (r = 0.68, n = 15, P less than 0.004) whereas serum iEpo values were not (r = 0.41, n = 12, P = 0.18). IGF-I could therefore be an important factor regulating erythropoiesis in uraemic patients, at least when associated with severe hyperparathyroidism.
Nephrol Dial Transplant 1992
PMID:Insulin-like growth factor I: a modulator of erythropoiesis in uraemic patients? 131 79


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>